Search Results

Helius Medical Technologies, Inc. announced that it will participate in the Spring MicroCap Rodeo Conference to be held on Thursday, June 6th in NYC.

Helius Medical Technologies, Inc., a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, announced results for the quarter ended March 31, 2024.

Helius Medical Technologies, Inc. announced the completion of site participation enrollment for its stroke registrational program in the U.S. with the addition of REHABOLOGYM, Neurology Center of New England, and MGH Institute of Health Professions.

Helius Medical Technologies, Inc. today announced the expansion of its clinical development program for the broadening of the labeling of its marketed PoNS device.

Helius Medical Technologies, Inc. today announced that the Company will release its first quarter 2024 financial results on Monday, May 13, 2024, after the market closes.

Helius Medical Technologies, Inc., a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, announced the first third-party reimbursement from a major insurance carrier for the Company’s Portable Neuromodulation Stimulator device.

Helius Medical Technologies, Inc. today announced the initiation of an open-label study for its registrational program in stroke.

Helius Medical Technologies, Inc. announced the pricing of a public offering of 804,999 shares of its Class A common stock and 2,047,222 Pre-Funded Warrants, each to purchase one share of Common Stock, together with accompanying Series A and Series B warrants to purchase up to an aggregate of 5,704,442 shares of Common Stock.

Helius Medical Technologies, Inc. announced that the Centers for Medicare & Medicaid Services posted proposed Medicare Durable Medical Equipment, Prosthetics, Orthotics, and Supplies fee schedule payment rates for the PoNS Controller and Mouthpiece to be discussed at the bi-annual Healthcare Common Procedure Coding System Public Meeting, scheduled for May 29, 2024.